{"denoms":[{"counts":[{"groupId":"BG000","value":"54"}],"units":"Participants"}],"groups":[{"description":"Fludarabine monophosphate, melphalan, Bortezomib: •Fludarabine will be administered at a dose of 30/mg/m2 IV daily for 4 days starting on transplant day -5.\n\n* Melphalan will be administered at a dose of 140 mg/m2 on transplant day-2\n* Bortezomib will be administered by rapid IV push at a dose of 1.6mg/m2 on days-4 and -1. The bortezomib should be given at least 20 hours after the melphalan.","id":"BG000","title":"Fludarabine, Melphalan, Bortezomib"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"18","upperLimit":"69","value":"56"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"54"}],"units":"Participants"}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"19"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"35"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"BG000","value":"54"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"denoms":[{"counts":[{"groupId":"BG000","value":"0"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Race and Ethnicity were not collected from any participant.","title":"Race and Ethnicity Not Collected","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"54"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"54"}],"units":"Participants"}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}]}